RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
@jamienholloway We know subtype drives the likelihood of ypCR. A recent publication showed that a small percentage have a different subtype on their residual disease. https://t.co/syLIOarAGF #bcsm
RT @DrSGraff: “Residual disease was noted in 31 cancers [treated with neoadjuvant therapy] (57.4%). Five of these (16.1%) had a change in t…
RT @DrSGraff: “Residual disease was noted in 31 cancers [treated with neoadjuvant therapy] (57.4%). Five of these (16.1%) had a change in t…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @DrSGraff: “Residual disease was noted in 31 cancers [treated with neoadjuvant therapy] (57.4%). Five of these (16.1%) had a change in t…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @DrSGraff: “Residual disease was noted in 31 cancers [treated with neoadjuvant therapy] (57.4%). Five of these (16.1%) had a change in t…
RT @DrSGraff: “Residual disease was noted in 31 cancers [treated with neoadjuvant therapy] (57.4%). Five of these (16.1%) had a change in t…
RT @DrSGraff: “Residual disease was noted in 31 cancers [treated with neoadjuvant therapy] (57.4%). Five of these (16.1%) had a change in t…
“Residual disease was noted in 31 cancers [treated with neoadjuvant therapy] (57.4%). Five of these (16.1%) had a change in tumor subtype” - important look at tumor subtypes. Should repeat markers be standard for patients that don’t have ypCR? #bcsm
Impact of #Neoadjuvant Chemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? Can it alter adjuvant treatment? @ASBrS @AnnSurgOncol
RT @pozoparilli: Los cambios que ocurren post neoadyuvancia en la expresión de los receptores hormonales y Her2 en el cáncer de mama, deben…
RT @pozoparilli: Los cambios que ocurren post neoadyuvancia en la expresión de los receptores hormonales y Her2 en el cáncer de mama, deben…
RT @pozoparilli: Los cambios que ocurren post neoadyuvancia en la expresión de los receptores hormonales y Her2 en el cáncer de mama, deben…
RT @pozoparilli: Los cambios que ocurren post neoadyuvancia en la expresión de los receptores hormonales y Her2 en el cáncer de mama, deben…
RT @pozoparilli: Los cambios que ocurren post neoadyuvancia en la expresión de los receptores hormonales y Her2 en el cáncer de mama, deben…
RT @pozoparilli: Los cambios que ocurren post neoadyuvancia en la expresión de los receptores hormonales y Her2 en el cáncer de mama, deben…
RT @pozoparilli: Los cambios que ocurren post neoadyuvancia en la expresión de los receptores hormonales y Her2 en el cáncer de mama, deben…
Los cambios que ocurren post neoadyuvancia en la expresión de los receptores hormonales y Her2 en el cáncer de mama, deben conducir a modificar el esquema de tratamiento. Por esto es necesario repetir la inmunohistoquímica en el tumor residual #mastólogo #
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
RT @AnnSurgOncol: NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://…
Personalized medicine!
NOVEMBER ISSUE:Impact of #NeoadjuvantChemotherapy on #BreastCancer Subtype: Does Subtype Change and, if so, How? https://t.co/vzzlWUZGYy @McMastersKelly @SocSurgOnc
Congratulations to Lucy De La Cruz, MD and her collaborators on their recent publication in @AnnSurgOncol https://t.co/xYO0yJkjU7 https://t.co/Oc5oldDXVK
Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy. #BreastCancer @ClinMedJournals https://t.co/yuqRQZZKmF